NPPA exempts Sun Pharma’s oncology injection from price control

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has exempted Sun Pharmaceutical Industries’ gemcitabine hydrochloride injection from price control in its last meeting on 30 October, according to minutes of the meeting.

The approval for the ready-to-use infusion bags of gemcitabine hydrochloride injection, which exhibits anti-tumor activity and is used to treat various kinds of cancer.

Under paragraph 32 of the Drug (Price Control) Order, 2013, the NPPA can exempt drugs from price control which are either new or have a new delivery system that is developed through indigenous research.

Sun Pharma got the approval for gemcitabine hydrochloride injection of 10mg/ml strength in ready to use infusion bags of 120ml, 140ml and 160 ml.

While the Standing National Committee on Medicines raised concerns that there was no clinical study to suggest that the product offered significant therapeutic advantage and increased efficacy as compared to other forms of the drugs, the NPPA pointed out that increased therapeutic advantage and efficacy were not pre-conditions for getting price control exemption for new drugs, as per the minutes.

The committee oversees revision of National List of Essential Medicines, which are drugs that come under price control.

As per information on the NPPA website, Sun Pharma sells gemcitabine 200mg powder for injection at ₹1,231.65 per pack.

The NPPA on 30 October also deferred its decision to exempt a cardiac stent developed by Meril Life Sciences Pvt Ltd from price control pending review of its efficacy as well as concerns raised over its safety.

Meril Life Sciences had filed a plea for exemption of bioresorbable vascular scaffold system MeRes100, which dissolves naturally in the body, from price control.

However, after the All India Drug Action Network raised health and safety concerns regarding usage of the stents, the matter was referred to the Drug Controller General (India), Director General of Indian Council for Medical Research and the health ministry.

Source:https://www.livemint.com/companies/news/nppa-exempts-sun-pharma-s-oncology-injection-from-price-control-11573551790562.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more